Monte Rosa Therapeutics, Inc.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$38.6M
- Total assets
- $448.7M
- Market cap
- $1.4B
- Operating margin
- -107.3%
- Net margin
- -96.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $75.6M
- Operating expenses
- $156.7M
- Operating income
- -$81.1M
- Income tax
- $2.6M
- Net income
- -$72.7M
Balance sheet
- Total assets
- $438.7M
- Current assets
- $377.4M
- Total liabilities
- $215.8M
- Current liabilities
- $156.9M
- Shareholders’ equity
- $222.9M
Cash flow
- Operating cash flow
- $42.0M
- Investing cash flow
- -$44.5M
- Financing cash flow
- $98.9M
- Net cash flow
- $96.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- Shares outstanding
- 81.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 24, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $38.6M.
- Trading 33% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Monte Rosa Therapeutics, Inc..
Write a review
News about Monte Rosa Therapeutics, Inc.
News & sentiment via Polygon.io
